Trials / Completed
CompletedNCT05697952
E1K Intra Articular(IA) Treatment for Knee Osteoarthritis
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of E1K After Single Dose in Patients With Knee Osteoarthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Ensol Bioscience · Industry
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and safety of pain relief treatment on knee osteoarthritis when administered E1K or placebo in patients with knee osteoarthritis aged 40 to 70 to determine the optimal dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E1K 1,200 ㎍/joint | Injection of E1K 1,200 ㎍/joint/ml on target lesion |
| DRUG | E1K 2,400 ㎍/joint | Injection of E1K 2,400 ㎍/joint/ml on target lesion |
| DRUG | placebo | Injection of 3ml saline on target lesion |
Timeline
- Start date
- 2022-06-13
- Primary completion
- 2023-11-29
- Completion
- 2023-11-29
- First posted
- 2023-01-26
- Last updated
- 2024-04-04
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05697952. Inclusion in this directory is not an endorsement.